Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Intrinsic Chemoresistance to Gemcitabine Is Associated with Decreased Expression of BNIP3 in Pancreatic Cancer

15 Apr 2005

Abstract excerpt

PURPOSE: Although chemotherapy with gemcitabine is a common mode of treatment of pancreatic cancer, 75% of patients do not benefit from this therapy. It is likely that the sensitivity of cancer cells to gemcitabine is determined by a number of different factors. EXPERIMENTAL DESIGN: To identify genes that might contribute to resistance to gemcitabine, 15 pancreatic cancer cell lines were subjected to gemcitabine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autophagy in Disease and Therapy
Share to Cell death mechanisms and regulation
Share to Pancreatic and Hepatic Oncology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 15837765
DOI: 10.1158/1078-0432.ccr-04-1785

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Intrinsic Chemoresistance to Gemcitabine Is Associated with Decreased Expression of BNIP3 in Pancreatic CancerPMID 15837765Read ↗

Multidrug resistance genes screening of pancreatic cancer based on sensitivity profile to chemotherapeutic drugsSemantic proximity Read ↗

Gemcitabine resistance by CITED4 upregulation via the regulation of BIRC2 expression in pancreatic cancerSemantic proximity Read ↗

Integrative Genomic Analysis of Gemcitabine Resistance in Pancreatic Cancer by Patient-derived Xenograft ModelsSemantic proximity Read ↗

The complement C3a/C3aR pathway is associated with treatment resistance to gemcitabine-based neoadjuvant therapy in pancreatic cancerSemantic proximity Read ↗

Identification of chemoresistance‐related mRNAs based on gemcitabine‐resistant pancreatic cancer cell linesSemantic proximity Read ↗

Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic CancerSemantic proximity Read ↗

LncRNA AB209630 inhibits gemcitabine resistance cell proliferation by regulating PI3K/AKT signaling in pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Intrinsic gemcitabine resistance in a novel pancreatic cancer cell line is associated with cancer stem cell-like phenotypeSemantic proximity Read ↗

PLK1 inhibition enhances gemcitabine-induced apoptosis through PLK1-dependent ERK1/2-BIM and AKT1/NOXA signals in pancreatic cancer cellsSemantic proximity Read ↗

Review. Molecular background of chemoresistance in pancreatic cancer.Semantic proximity Read ↗

MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma.Semantic proximity Read ↗

A miRNA Signature of Chemoresistant Mesenchymal Phenotype Identifies Novel Molecular Targets Associated with Advanced Pancreatic CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.